

## THC BioMed Form 7

### MONTHLY PROGRESS REPORT

March 2021

Name of CSE Issuer **THC BioMed Intl Ltd. ("THC BioMed")**  
Trading Symbol: **THC**  
Number of Outstanding Listed Securities **163,838,556 common shares and 49,651,665 reserved for Issuance**  
Date: **April 1, 2021**

#### Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**During the period, the Issuer announced that it had shipped its THC Kiss Gummies to B.C. cannabis stores.**

**THC Kiss Gummies are infused with the Company's propriety Kiss cannabis extract. Each package of THC Kiss Gummies contains 4 gummies with a total of 10 mg of THC.**

**The Issuer also announced that it had updated its website and e-commerce platform to better suit the recreational cannabis market.**

**On March 17<sup>th</sup>, the Issuer announced that it had engaged a consultant to carry out an enhancement project on the Issuer's automated cannabis cylinder machine to improve cannabis cylinder production and add automated packaging to the process. The Issuer has granted the consultant 500,000 stock options upon his engagement. The options are subject to a milestone vesting schedule described below and may be exercised at a price of CAD \$0.165 per common share, for a period of 2 years from the date of issuance.**

**The options will vest as follows:**

- **50,000 upon grant;**
- **50,000 upon restarting production following the enhancement project;**
- **100,000 upon THC BioMed's approval of the cannabis cylinders produced following the enhancement project; and,**
- **300,000 upon the completion of three batches of cannabis cylinders/Cannasticks, rolled and packaged, following the enhancement project.**

**The consultant has more than 30 years' experience in use of the type of automated machine used by THC BioMed in making its cannabis cylinders/Cannasticks. He was instrumental in originally adapting the Issuer's machine to cannabis from its prior use.**

**The Company intends to use the increased production for its own Cannasticks or to offer toll production to other Licensed Producers.**

FORM 7 – MONTHLY PROGRESS REPORT

2. Provide a general overview and discussion of the activities of management.

**Management continues to work on the conduct of the company's business plan, growth and harvest of product, new product testing and expansion plans.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**THC Kiss Gummies are now available in B.C. cannabis stores.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**THC BioMed has received a letter of authorization from the Autorités des Marchés Publics ("AMP"), Quebec's Public Markets Authority. This authorization is granted by AMP pursuant to Quebec's *Act Respecting Contracting by Public Bodies* and permits THC BioMed to enter into contracts with Quebec's Société québécoise du cannabis ("SQDC.") Pursuant to Quebec's *Cannabis Regulation Act*, only the SQDC may purchase cannabis from a federally licensed cannabis producer and sell it to the public in Quebec.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None.**

8. Describe the acquisition of new customers or loss of customers.

**The Issuer has continued to register new patients.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

**None.**

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

**None, except in the ordinary course of business.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
<b>Options</b>	<b>500,000</b>	<b>The options may be exercised at a price of CAD \$0.165 per common share, for a period of two years. The options will vest 50,000 upon grant, 50,000 upon restarting production following the enhancement project, 100,000 upon THC BioMed's approval of the cannabis cylinders produced following the enhancement project and 300,000</b>	<b>Not applicable</b>

		upon the completion of three batches of cannabis cylinders/Cannasticks rolled and packaged, following the enhancement project.	
--	--	--	--

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

**None.**

16. Provide details of any changes in directors, officers or committee members.

**None.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer's most recent Management's Discussion and Analysis under the titles "Financial Instruments and Risk Management" and "Other Risks and Uncertainties", which is available on SEDAR at [www.sedar.com](http://www.sedar.com).**

**The outbreak of COVID-19 has significantly increased economic uncertainty. In addition, public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions and the adoption of remote working, have impacted our business and operations. COVID-19 is impacting our contractors' ability to provide services to us, including professional services such as accounting and auditing due to social distancing measures.**

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **April 1, 2021**

**John Miller**

Name of Director or Senior Officer

***“John Miller”***

Signature

**President and CEO**

Official Capacity

<b><i>Issuer Details</i></b>		
Name of Issuer: <b>THC BioMed Intl Ltd.</b>	For Month End <b>February</b>	Date of Report: YYYYMMDD <b>2021/04/01</b>
Issuer Address: <b>P.O. Box 20033 Towne Centre</b>		
City/Province/Postal Code: <b>Kelowna, BC V1Y 9H2</b>	Issuer Fax No.: <b>N/A</b>	Issuer Telephone No. <b>(250) 870-2512</b>
Contact Name: <b>John Miller</b>	Contact Position: <b>President &amp; CEO</b>	Contact Telephone No. <b>(250) 870-2512</b>
Contact Email Address: <b>info@thcbiomed.com</b>	Web Site Address: <b>www.thcbiomed.com</b>	

FORM 7 – MONTHLY PROGRESS REPORT